Semaglutide: 2026 Ozempic, Wegovy & Compound Guide

Semaglutide: 2026 Ozempic, Wegovy & Compound Guide
Educational use only. This article is informational and does not constitute medical advice. Peptide dosing decisions should be made in consultation with a licensed physician familiar with your medical history. Always verify any dose with your prescribing physician before drawing or administering. Some peptides discussed are not FDA-approved for human use; legal and regulatory status varies by jurisdiction.
Nutrition matters as much as dose. On any GLP-1, protein intake and resistance training are what determine whether the weight you lose is fat or muscle. Our free GLP-1 Nutrition & Diet Guide covers evidence-based protein targets, meal timing when appetite is suppressed, and the muscle-preservation research from SURMOUNT-1 and STEP-1.

If your prescriber just handed you a semaglutide prescription. Ozempic, Wegovy, or Rybelsus, or you are weighing whether to start, this is the dosing guide we wish you had on day one. Semaglutide is the most prescribed GLP-1 receptor agonist in modern medicine, with three FDA-approved brands, two delivery routes (subcutaneous injection and oral tablet), and a lively shadow market of compounded vials sold by telehealth pharmacies. Each product has its own indication, its own titration schedule, and its own set of pitfalls. In the next 2,500 words we walk through what semaglutide is, how it works, the FDA-approved titration for each brand, the reconstitution math you need if you are using compounded vials, the side effects most people actually experience, and the regulatory landscape after the October 2024 shortage resolution. Then we hand you off to your prescriber, where dosing decisions belong.

Table of Contents

What is semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk. It is sold in three FDA-approved branded forms, each with a distinct indication and dosing schedule:

  • Ozempic , once-weekly subcutaneous injection, approved for type 2 diabetes, cardiovascular risk reduction, and chronic kidney disease in T2DM.
  • Wegovy , once-weekly subcutaneous injection at higher doses, approved for chronic weight management; cardiovascular risk reduction in overweight or obese adults with established CVD (added March 2024); and pediatric obesity (≥12 years, BMI ≥95th percentile, FDA approved December 2022). Wegovy received FDA accelerated approval for noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis on August 15, 2025, based on the Phase 3 ESSENCE trial.
  • Rybelsus , once-daily oral tablet, approved for type 2 diabetes.

All three contain the same active molecule. The differences are in dose strength, formulation, and what condition they are labeled to treat.

How semaglutide works

GLP-1 (glucagon-like peptide-1) is a gut hormone released in response to food. It signals your pancreas to release insulin, tells your brain you are full, and slows the rate at which food empties from your stomach. Semaglutide mimics natural GLP-1 but with a half-life measured in days instead of minutes, which is what allows once-weekly dosing.

The plasma half-life is approximately 165 hours, or about 7 days (Hall et al., Clin Pharmacokinet 2018; 57:1571–1580). Steady-state blood levels are reached at 4–5 weeks of weekly dosing at any given dose, which is why every titration step is held for at least 4 weeks before stepping up. Time to peak concentration after a subcutaneous injection is 1–3 days.

Oral semaglutide (Rybelsus) overcomes the normal destruction of peptides in the gut by being co-formulated with SNAC, an absorption enhancer. Bioavailability is approximately 1% , which sounds bad until you realize the dose is 14 mg daily versus 2.4 mg weekly for the injectable. The catch is that this 1% bioavailability is fragile: any food, drink, or other oral medication taken too soon after the tablet collapses absorption.

Dosing protocol

Ozempic (T2DM)

Per the Ozempic USPI (Novo Nordisk, revised January 2025):

PhaseWeeksWeekly DoseNotes
Initiation1–40.25 mgTolerability only, not therapeutic
Step 15–80.5 mgFirst therapeutic dose
Step 29–120.5 mg or 1.0 mgMay continue or escalate
Step 3 (max)13+2.0 mgAdded to label March 2022

Ozempic ships in three pen strengths: 0.25/0.5 mg pen, 1 mg pen, and 2 mg pen. Each pen delivers four weekly doses. Maximum approved dose is 2.0 mg/week.

Wegovy (chronic weight management)

Per the Wegovy USPI (Novo Nordisk, revised August 2025), Wegovy uses a mandatory 5-step titration:

MonthWeeksWeekly Dose
Month 11–40.25 mg
Month 25–80.5 mg
Month 39–121.0 mg
Month 413–161.7 mg
Month 5+ (maintenance)17+2.4 mg

Maximum approved dose is 2.4 mg/week. If you do not tolerate 2.4 mg, the label explicitly permits maintenance at 1.7 mg. Pediatric dosing (≥12 years, BMI ≥95th percentile) follows the same titration as adults, the December 2022 approval was based on the STEP TEENS trial (Kelly et al., NEJM 2022; 387:2245–2257).

Rybelsus (oral, T2DM)

Per the Rybelsus USPI (Novo Nordisk, revised June 2025):

PhaseWeeksDaily Dose
Initiation1–43 mg (not therapeutic)
Step 15–87 mg
Maintenance9+14 mg (current label maximum)

Note: In late 2025, the FDA approved oral semaglutide 25 mg as Wegovy tablets for chronic weight management (OASIS-4 trial); commercial launch occurred in January 2026 (~$149/month self-pay through NovoCare). The 50 mg dose remains under FDA review. Rybelsus also gained an FDA-approved cardiovascular risk reduction indication in October 2025 (SOUL trial).

Critical administration rule: Take Rybelsus on an empty stomach with no more than 120 mL of plain water, then wait at least 30 minutes before food, drink, or any other oral medication. Bioavailability collapses if this rule is violated, you can functionally negate the dose by drinking coffee too soon.

Missed dose handling

  • Ozempic and Wegovy: If less than 5 days since the missed dose, take it as soon as you remember; resume your regular schedule. If more than 5 days, skip and take the next dose on its regular day. (Ozempic USPI §2.3, Wegovy USPI §2.4.)
  • Rybelsus: Skip the missed dose entirely; resume the next day. Do not double up.
  • If a gap exceeds 2 weeks, Novo Nordisk’s prescriber Q&A suggests restarting at a lower titration step due to GI side-effect return.

Reconstitution math for compounded vials

The Reconstitution Math, Visualized10mgvial+2mLBAC water=5mg/mLconcentration→100units5mg on U-100

This section only applies to compounded semaglutide from a 503A or 503B pharmacy, typically dispensed via a telehealth platform. Branded Ozempic and Wegovy come as pre-filled pens, no math, no mixing.

The two formulas you need

Concentration: total mg in vial ÷ mL of bacteriostatic water (BAC water) added = mg per mL.

Units on a U-100 syringe: (dose in mg ÷ concentration in mg/mL) × 100. The result is the number of insulin-syringe units to draw.

Common compounded semaglutide configurations

Vial totalBAC water addedResulting concentrationExample dose volume
2 mg1 mL2 mg/mL0.25 mg = 0.125 mL (12.5 units)
5 mg2 mL2.5 mg/mL0.5 mg = 0.20 mL (20 units)
10 mg2 mL5 mg/mL1.0 mg = 0.20 mL (20 units)
10 mg1 mL10 mg/mL2.0 mg = 0.20 mL (20 units)
15 mg3 mL5 mg/mL (Henry Meds default)1.0 mg = 0.20 mL (20 units)

A worked example

You have a 10 mg vial. Your prescriber says to add 2 mL of BAC water. Concentration is 10 ÷ 2 = 5 mg/mL. Your prescribed dose is 1.0 mg. Volume = 1.0 ÷ 5 = 0.20 mL. On a U-100 syringe, that is 20 units.

Our peptide reconstitution calculator (live now at calculator.thepeptidetoolkit.com) handles this in two clicks and warns you if your inputs would produce a volume too small to measure or too large for one syringe. What it cannot do is decide your dose, that is your prescriber’s job.

Reconstitution mistakes to avoid

  • Confusing mg with units. The U-100 syringe is marked in insulin units, not milligrams. 100 units = 1 mL. Patients reading the markings as milligrams have injected 10× their intended dose.
  • Wrong BAC water volume. If the prescriber said 2 mL and you added 1 mL, every dose is now twice as concentrated.
  • Sterile water in a multi-dose vial. Use bacteriostatic water (with 0.9% benzyl alcohol) for any vial used over multiple weeks. Sterile water has no preservative and supports microbial growth past 24 hours.
  • Shaking the vial. Semaglutide is a peptide; vigorous shaking foams and denatures it. Swirl gently. Allow 1–2 minutes to fully dissolve.
  • Drawing immediately after adding water. If the powder has not fully dissolved, you under-dose.
  • Skipping refrigeration after reconstitution. Label-supported stability is 28 days at 2–8°C.
  • Reusing needles. Beyond contamination, reused needles core the vial stopper and introduce dose-volume error.

Community dosing patterns

The biohacker and telehealth communities discuss several practices that diverge from the FDA label:

  • Micro-titration: 0.10–0.15 mg increments instead of the 0.25 → 0.5 → 1.0 jumps, citing better GI tolerance.
  • Hold doses: Pausing escalation at the lowest effective dose rather than driving toward 2.4 mg.
  • Split dosing: Some users split the weekly dose in two (e.g., 1.0 mg twice weekly = 2.0 mg/week) to reduce peak side effects. This is off-label and not supported by pharmacokinetic studies, semaglutide’s flat 7-day half-life means kinetic benefit is minimal, though it may reduce Cmax.

None of these are endorsed by Novo Nordisk or the FDA label. Discuss with your prescriber before deviating from labeled titration.

Side effects and management

From the STEP 1 trial (Wilding et al., NEJM 2021; 384:989–1002), the most common Wegovy side effects (≥5% incidence) were:

  • Nausea, 44%
  • Diarrhea , 32%
  • Vomiting , 25%
  • Constipation , 24%
  • Abdominal pain , 20%
  • Headache , 14%
  • Fatigue , 11%
  • Dyspepsia, eructation, gastroenteritis

Most GI side effects peak in the first 24–48 hours after each injection and recede across the week. They are also dose-dependent and front-loaded , the first 1–2 weeks of each new step are the worst.

Boxed warning and notable risks

  • Thyroid C-cell tumors , class boxed warning. Rodent data; human relevance unclear. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2.
  • Acute pancreatitis , rare (~0.2% per year).
  • Gallbladder disease , ~2.6% on Wegovy versus 1.2% on placebo in STEP 1.
  • Acute kidney injury , typically secondary to volume depletion from vomiting.
  • Suicidal ideation , both EMA and FDA reviews (2023–2024) found no causal signal, but post-marketing surveillance continues.
  • NAION (non-arteritic anterior ischemic optic neuropathy) , Hathaway et al., JAMA Ophthalmol 2024 found increased risk. The European Medicines Agency (EMA/PRAC) added NAION as a very rare side effect to semaglutide product labels in June 2025; FDA action on US prescribing information is pending as of early 2026.

Practical management strategies

  • Hold the current titration step for an extra 2–4 weeks if you are not tolerating it.
  • Some prescribers co-prescribe ondansetron during early titration.
  • Hydrate aggressively , 2–3 L of water daily. Volume depletion is the leading cause of AKI on this drug class.
  • Smaller, lower-fat meals reduce nausea more than any other dietary change.
  • Down-titrating one step is explicitly endorsed by the Wegovy label if a higher dose is intolerable.

Drug interactions

Drug interactions to know

Major Insulin (basal and prandial)
How: Additive hypoglycemia risk in patients with type 2 diabetes. Hypoglycemia observed in SUSTAIN trials when semaglutide 0.5 mg and 1 mg combined with insulin.
FDA Ozempic and Wegovy labels §5.4 and §7.1. Reduce insulin dose at semaglutide initiation; titrate based on glucose monitoring. Source: FDA Ozempic PI 2025 (209637s035); FDA Wegovy PI 2025 (215256s026).
Major Sulfonylureas (glipizide, glyburide, glimepiride)
How: Additive hypoglycemia. Sulfonylureas drive glucose-independent insulin secretion; semaglutide adds glucose-dependent insulinotropic effect plus delayed gastric emptying.
FDA Ozempic and Wegovy labels §7.1. Consider sulfonylurea dose reduction at semaglutide initiation. Source: FDA Ozempic PI 2025; Wegovy PI 2025.
Moderate Meglitinides (repaglinide, nateglinide)
How: Same insulin-secretagogue mechanism as sulfonylureas — additive hypoglycemia.
FDA Ozempic label §7.1 (insulin secretagogues as a class). Reduce dose at semaglutide initiation. Source: FDA Ozempic PI 2025.
Moderate Warfarin and coumarin anticoagulants (warfarin, acenocoumarol, phenprocoumon)
How: Healthy-volunteer DDI study showed no clinically relevant change in warfarin PK, peak concentration, time to peak, or INR. However, postmarketing reports describe decreased INR with concomitant acenocoumarol.
FDA Ozempic label §12.3 and §7.2. More frequent INR monitoring may be considered when semaglutide is initiated in patients taking warfarin or other coumarin derivatives. Source: FDA Ozempic PI 2025 §12.3.
Moderate Levothyroxine (Rybelsus / oral semaglutide only)
How: Levothyroxine total exposure (AUC) increased 33% (90% CI 125-142%) when coadministered with Rybelsus. Mechanism is altered gastric absorption window related to SNAC co-formulation.
FDA Rybelsus label §7.2 and §12.3. Monitor TSH 6-8 weeks after reaching maintenance semaglutide dose; adjust levothyroxine dose as needed. Subcutaneous Ozempic/Wegovy do NOT show this PK effect. Source: FDA Rybelsus PI 2025 (213051s024).
Moderate Oral medications generally — narrow therapeutic index (digoxin, phenytoin, lithium, cyclosporine, tacrolimus)
How: Delayed gastric emptying alters rate and occasionally extent of oral absorption. With Rybelsus there is an additional gastric-pH absorption-window effect.
FDA Ozempic label §7.2; FDA Rybelsus label §7.2. Monitor patients on narrow-therapeutic-index oral drugs. Rybelsus must be taken at least 30 minutes before any other oral medication, food, or liquid. Source: FDA Rybelsus PI 2025 §2.1, §7.2.
Monitor Oral hormonal contraceptives (ethinyl estradiol / levonorgestrel) — subcutaneous semaglutide
How: DDI study with ethinyl estradiol/levonorgestrel showed no clinically relevant change in PK at steady state with subQ semaglutide. Delayed gastric emptying is greatest after first dose and after escalation.
FDA Ozempic label §12.3 and §7.2. No dose adjustment for subcutaneous semaglutide, but counsel on first-dose absorption uncertainty. Source: FDA Ozempic PI 2025 §12.3.
Monitor Metformin
How: No clinically relevant PK interaction at steady state.
FDA Ozempic label §12.3 and §7.2. No dose adjustment required. Source: FDA Ozempic PI 2025 §12.3.
Monitor Digoxin
How: Single-dose DDI study — no clinically relevant change in digoxin exposure.
FDA Ozempic label §12.3 and §7.2. No dose adjustment but monitor digoxin levels in setting of severe GI adverse events. Source: FDA Ozempic PI 2025 §12.3.
Monitor Atorvastatin and other statins
How: Atorvastatin DDI study — no clinically relevant PK change.
FDA Ozempic label §12.3 and §7.2. No dose adjustment required. Source: FDA Ozempic PI 2025 §12.3.
Major General anesthesia / deep sedation (preoperative aspiration risk)
How: Delayed gastric emptying produces residual gastric contents despite NPO; rare postmarketing reports of pulmonary aspiration.
FDA Wegovy label §5.x and Ozempic label §5.x (class labeling added 2024). ASA 2023 consensus: consider holding once-weekly semaglutide one dose (7 days) prior to elective procedures; once-daily Rybelsus held on day of procedure. Multisociety 2024 update (PMID: 39550027) emphasizes shared decision-making. Source: FDA Ozempic/Wegovy PI 2025; ASA Consensus 2023.
Major Other GLP-1 receptor agonists / incretin agonists (tirzepatide, liraglutide, dulaglutide, exenatide, retatrutide, orforglipron)
How: Duplicate therapy — no additional efficacy, additive GI and aspiration risk.
FDA Ozempic / Wegovy labels — not studied in combination. Use one incretin agent at a time. Source: FDA Ozempic PI 2025.
Major Pramlintide (Symlin)
How: Additive delayed gastric emptying and additive hypoglycemia when used with insulin.
Not studied in combination. Avoid. Mechanism-based class precaution. Source: Symlin PI; FDA Ozempic PI 2025 §7.2.
Moderate Drugs causing pancreatitis (valproate, azathioprine, didanosine, pentamidine, high-dose corticosteroids, DPP-4 inhibitors)
How: Additive risk of acute pancreatitis. SUSTAIN and STEP trials reported pancreatitis cases on semaglutide.
FDA Ozempic and Wegovy labels §5.3 (pancreatitis precaution). Discontinue semaglutide if pancreatitis suspected. Source: FDA Ozempic PI 2025 §5.3.
Moderate Drugs altering gastric pH — PPIs (omeprazole, esomeprazole, pantoprazole), H2 blockers (famotidine, ranitidine), antacids (Rybelsus only)
How: Rybelsus absorption depends on transient gastric pH change from SNAC co-formulation. Omeprazole 40 mg daily increased semaglutide AUC and Cmax modestly in DDI study, but interpretive guidance from label is that no dose adjustment is required.
FDA Rybelsus label §12.3. Take Rybelsus per its labeling (empty stomach, ≤120 mL water, then 30-min fast); PPI use does not require dose adjustment but counsel on timing. Source: FDA Rybelsus PI 2025 §12.3.
Monitor Alcohol (ethanol)
How: Additive GI adverse effects; potential additive hypoglycemia when combined with insulin or sulfonylureas; pancreatitis risk factor.
FDA Ozempic label §5.3 (pancreatitis precaution). Advise moderation. Source: FDA Ozempic PI 2025.

Educational summary only, not medical advice. Consult your prescriber. See full interactions lookup.

Cycle Lengths

Not typically cycled. Semaglutide is a chronic maintenance therapy per FDA prescribing information for Ozempic, Wegovy, and Rybelsus. Interrupting therapy typically causes weight regain — the STEP-4 trial documented participants who discontinued Wegovy regained roughly two-thirds of lost weight over the following 48 weeks.

Intentional pauses users report: pregnancy planning (semaglutide is not recommended during pregnancy — the FDA label advises a washout of 2 months before conception), scheduled surgery under general anesthesia (retained gastric contents concern; some anesthesiologists request holding the last dose 1 week pre-op), and stepping down to a maintenance dose after reaching goal weight (some users taper from Wegovy 2.4 mg to a lower titration dose long-term).

Missed doses: per FDA label, if a dose is missed and the next scheduled dose is more than 48 hours away, take the missed dose as soon as remembered. If less than 48 hours until the next scheduled dose, skip the missed dose and resume the normal schedule. Do not double-dose.

Lab Monitoring

Semaglutide is FDA-approved with a well-characterized monitoring profile. Both the metabolic effect (glucose, weight, lipids) and the class-associated risks (thyroid, pancreatic, gallbladder, retinopathy) call for structured lab tracking.

Baseline (before starting): HbA1c, fasting glucose, lipid panel, comprehensive metabolic panel (CMP) with LFTs and renal function, CBC, TSH, amylase and lipase if pancreatic risk factors are present, and serum calcitonin if there is a personal or family history of medullary thyroid carcinoma (MEN 2 and personal MTC history are boxed contraindications per FDA label).

During use: HbA1c and lipid panel every 3 months during titration, then every 6 months once stable. CMP every 3-6 months. Weight and blood pressure monthly during titration. Gallbladder ultrasound if new right-upper-quadrant pain (semaglutide increases gallbladder disease risk per FDA label).

What to flag to a physician: persistent severe abdominal pain (pancreatitis rule-out), right-upper-quadrant pain (gallbladder), new neck mass or dysphagia (thyroid nodule evaluation), worsening vision (diabetic retinopathy progression documented in T2D users), pregnancy or plans for pregnancy.

For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.

Storage & Travel

Storage

Sealed prefilled pens (Ozempic, Wegovy): refrigerate 2-8°C (36-46°F) until first use. After first use, pens are stable at room temperature up to 30°C (86°F) — 56 days for Ozempic, 28 days for Wegovy per FDA prescribing information. Keep the pen cap on when not in use, protected from light.

Rybelsus oral tablets: room temperature 20-25°C (68-77°F); keep in the original blister packaging until dose time. Excursions to 15-30°C acceptable per FDA label.

Compounded vials (semaglutide sodium powder + BAC water): refrigerate reconstituted 2-8°C (36-46°F) and use within 28 days per USP <797> peptide stability guidance. Lyophilized powder freezer -20°C long-term. Never freeze a reconstituted vial or FDA-approved pen.

Travel

Domestic flights: unopened pens are stable at room temperature for the full 28-56 day window depending on product — refrigeration is not required for most domestic trips. TSA permits medications through security; declare and keep pens in original labeled boxes with pharmacy label visible. In-use pens travel in an insulated bag with a small ice pack in hot climates.

International travel: carry the FDA-labeled prescription bottle or pen box, a physician’s letter listing the medication and dose, and a summary of the treatment purpose. Some countries require import declaration for injectable medications. Wegovy and Ozempic are approved in most major markets under their brand names.

Road trips: keep pens in the cabin, not the trunk (trunk temps regularly exceed 40°C in summer). Insulated bag inside a hotel mini-fridge for multi-day stays.

Emergency out-of-fridge: a pen exposed to room temperature beyond its labeled window (56d for Ozempic, 28d for Wegovy) should be discarded per FDA guidance — potency is not guaranteed. Contact the pharmacy for a replacement.

Common stacks and combinations

Within FDA-approved use, semaglutide is routinely combined with metformin, SGLT2 inhibitors, and statins. None of these require dose adjustment of semaglutide.

Two combinations require special attention:

  • Sulfonylureas and insulin. Adding semaglutide raises hypoglycemia risk. Most prescribers reduce the sulfonylurea or basal insulin dose at initiation.
  • Oral medications with narrow absorption windows. Slowed gastric emptying can blunt absorption of oral contraceptives and some antibiotics during titration.

Patients curious about switching from semaglutide to tirzepatide can review our dedicated GLP-1 conversion guide for ratios and the standard switch protocol.

2026 regulatory status

Compounded semaglutide is the most actively contested area of GLP-1 prescribing in 2026:

  • October 2024: FDA declared the semaglutide shortage resolved, removing the legal basis for routine 503A/503B compounding of “essentially a copy” of branded semaglutide.
  • 2025: Most major telehealth compounders pivoted to “personalized” formulations , most commonly semaglutide combined with B12 or another active ingredient , claiming this falls outside the “essentially a copy” definition. The legal status remains contested at the FDA and at state pharmacy boards.
  • 2026 (current): Compounded semaglutide availability and legality vary materially by state. Patients should ask their telehealth provider directly whether the formulation is compliant in their state, and request the compounding pharmacy’s certificate of analysis.

Branded Ozempic, Wegovy, and Rybelsus are FDA-approved and unaffected by these developments.

Cost considerations

ProductCash price (April 2026)Notes
Ozempic~$950–$1,100/monthOne pen
Wegovy~$1,350/monthCoverage variable for obesity
Rybelsus~$1,000/monthDaily oral
Compounded semaglutide via telehealth$150–$350/monthHighly variable; legal status varies by state

Insurance is the single biggest variable. Medicare Part D does not cover GLP-1s for obesity alone , the Treat and Reduce Obesity Act remains stalled in Congress as of April 2026. However, Wegovy is covered for cardiovascular risk reduction in patients with established CVD per the CMS memo of March 2024. Commercial coverage for the obesity indication is carve-out-dependent , roughly 40–50% of large employer plans cover Wegovy in 2026 (Mercer 2025 Survey).

Frequently asked questions

Are Ozempic and Wegovy the same drug?

Same active molecule (semaglutide), different dose strengths and different FDA-approved indications. Ozempic maxes out at 2.0 mg/week and is approved for T2DM and CV risk reduction; Wegovy goes to 2.4 mg/week and is approved for obesity, CV risk in CVD, and pediatric obesity ≥12 years.

What is the maximum semaglutide dose?

2.0 mg/week for Ozempic, 2.4 mg/week for injectable Wegovy, and 14 mg/day for Rybelsus (T2D label). Oral Wegovy 25 mg/day for obesity was FDA-approved in late 2025; oral 50 mg remains under review.

What if I miss a dose?

Ozempic and Wegovy: if less than 5 days since the missed dose, take it now and resume your normal schedule; if more than 5 days, skip it. Rybelsus: skip the missed dose, resume the next day. Never double up. If a gap exceeds 2 weeks, your prescriber will likely restart at a lower step.

Can I switch from semaglutide to tirzepatide?

Yes, and many patients do. There is no FDA-validated conversion table, but the standard clinical heuristic puts 1.0 mg semaglutide roughly equivalent to 5–7.5 mg tirzepatide, and 2.4 mg semaglutide roughly equivalent to 10–12.5 mg tirzepatide. See the full table in our GLP-1 conversion guide.

Why do I have to wait 30 minutes after taking Rybelsus?

Rybelsus uses an absorption enhancer (SNAC) to push semaglutide across the stomach lining. Bioavailability is only ~1% even when used correctly, and any food, drink, or other oral medication taken too soon collapses absorption further. The 30-minute wait is non-negotiable for the drug to work.

Is compounded semaglutide legal in 2026?

It depends on the state and the formulation. After the October 2024 shortage resolution, routine 503A/503B compounding of “essentially a copy” of branded semaglutide became restricted. Many compounders now sell “personalized” formulations such as semaglutide + B12. Whether these comply with FDA and state pharmacy law is contested. Ask your telehealth provider directly.

Where do I inject semaglutide?

Subcutaneously into the abdomen, thigh, or back of the upper arm. Rotate sites weekly.

Will I gain the weight back if I stop?

Most likely yes. The STEP 1 extension and similar trials show roughly two-thirds of lost weight returns within a year of discontinuation. Semaglutide treats obesity as a chronic condition; like medications for hypertension, the effect is present while the drug is on board.

Disclaimer: This article is for educational purposes only. It is not medical advice and is not a substitute for consultation with a licensed healthcare provider. Dosing decisions , including starting, titrating, switching, or stopping semaglutide , must be made with your prescribing physician. Compounded GLP-1 medications are subject to evolving FDA enforcement and state-level regulation; their legal availability may have changed since this page was published. Always read your medication’s FDA-approved prescribing information and follow your prescriber’s instructions.

Research-peptide buyer’s note (read before purchasing). Most Semaglutide Dosing Guide sold online is labeled “for research use only” and is not FDA-approved for human administration. If you choose to purchase research-grade product:
  • Demand a current third-party Certificate of Analysis (CoA) listing peptide identity (mass spec), purity ≥98%, and endotoxin testing.
  • Verify the lyophilized vial weight matches what’s printed – under-filled vials are the most common form of dose-cheating in this market.
  • Storage: Compounded semaglutide is widely sold; pharmaceutical Ozempic / Wegovy is the FDA-approved option.
  • Typical research route: subcutaneous (weekly).
  • Compounded semaglutide salts (sodium, acetate) have not been characterized in human trials and FDA has issued warnings about these forms specifically.
  • “Research-use-only” labeling has legal weight – self-administration may violate state and federal law in your jurisdiction.

References

  • U.S. Food and Drug Administration. Ozempic (semaglutide) prescribing information. DailyMed.
  • U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. DailyMed.
  • U.S. Food and Drug Administration. Rybelsus (semaglutide tablets) prescribing information. DailyMed.
  • Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. NEJM.
  • Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. NEJM.
  • Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed.
  • Newsome PN, Sanyal AJ, et al. Semaglutide in nonalcoholic steatohepatitis (ESSENCE). N Engl J Med. 2024-2025. PubMed.
  • Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in type 2 diabetes (FLOW). N Engl J Med. 2024. PubMed.
  • U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. FDA.
  • European Medicines Agency. PRAC review of GLP-1 receptor agonists and risk of NAION. EMA.
  • American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. Diabetes Journals.

Stay current on peptide research.

Monthly updates on FDA reclassification news, new dosing protocols, and calculator features. No spam, unsubscribe anytime.

Peptide updates + FDA alerts

Monthly peptide updates and important FDA alerts. No spam, unsubscribe anytime.

Join peptide patients and biohackers getting research updates straight to their inbox.

Authoritative Sources

This guide draws on peer-reviewed clinical research and FDA prescribing information. For primary source verification, consult these directly:

Similar Posts